COMPANY OVERVIEW Since Pfizer was founded by cousins Charles Pfizer and Charles Erhart in 1849.

Pfizer has remained dedicated to discovering and developing new, and better, ways to prevent and treat disease and improve health and well-being for people around the world. From the miracle of penicillin to important medications Pfizer focuses on meeting the world's diverse health needs. Pfizer is leader in human health, primary care, specialty care, vaccines and biologics.

Pfizer Slogan
A slogan is a short, memorable catch phrase, tagline or motto used to identify a product or company in advertisements. The advertising slogan, or business slogan most associated with Pfizer, is: "Pfizer Quality."

Pfizer Mission Statement: "We will become the world's most valued company to patients, customers, colleagues, investors, business partners, and the communities where we work and live."
Q.1. Define the Local Situation of Pfizer Pakistan?

Pfizer first set its foot in Pakistan in the 50s and worked with a local distributor through the early 60s. On 8th of September 1961 Pfizer, established itself as a manufacturing facility in Pakistan by acquiring another incorporated pharmaceutical company. After a few more mergers and acquisitions, today the group of Companies that operate under the name of Pfizer leads in manufacture and marketing of research based pharmaceutical products in the country and ranks as a group, at number 3 in the local market.

Q.2. What should be the global strategy of Pfizer in Future?

Pfizer should develop an R&D strategy along with competitive strategy to meet current challenges and position itself for high performance in the years ahead. In the end 2013 most of the patents will expire and due to decreased focus on R&D Pfizer will suffer a lot. Looking at the financial reports of Pfizer their revenue for 2011 was 67.425 billion dollars with total stockholders equity over $82bn. 1 This alone puts PF far in the lead of their nearest competitor, Johnson & Johnson, with 15.2% market share.

2. With a strong revenue stream, they have the ability to further retain earnings into research and development, ultimately undermining threatening companies like Merck and GlaxoSmithKline 3. Pfizer should go for diversification in various other areas like organic food, medical instruments etc. 4. the most important step would be to focus on emerging markets like Asia as whole and china in particular. This will give a new birth to the firm. In General they should go for
New Products & technologies

Intellectual Property Protection

Q.3. How should Pfizer do in order to cope up the problem potential and existing problems? Pharmaceutical companies must react and adapt to the changing market years in the future as opposed to the current situation. Pfizer must forecast potential dangers facing their market after drugs pass clinical trials. This has recently become a problem for Pfizer Inc. In the last few years they have watched their most popular drugs, Blockbusters, lose their patents to less expensive generic alternatives. They reacted to this by downsizing the R&D department, causing a lack of efficiency and future success. Even though Pfizer has secured the image of an upward motion with their stockholders, their future earnings as the industry leader is in serious danger. The good news is; there is a solution. Pfizer can reinstate the former power of the R&D department along with a few efficiency driving factors related to a drugs potential for success. First, Pfizer can reinstate the thousands of jobs downsized in the last couple years. Second, Pfizer can prioritize certain manufacturing labs to recreate the fundamental categories of blockbuster pharmaceuticals. Q.4. What should Pfizer do in the scenarios of multiple mergers and acquisitions? Pfizer has the huge assets portfolio, the can acquire and merge with many shining pharmacy firms. This is the requirement of this critical situation where they have no molecule in R&D and the patents will expire soon. The acquisition of Wyeth is the good step because Wyeth will bring to Pfizer a number of marketed products and pipeline candidates but is unlikely to address the Long neglected by drug companies as lowmargins therapies, the vaccines market was transformed by the launch of Wyeths

fundamental loss of loss of R&D productivity. Pfizer has identified six high-potential disease areas that would provide the companys future growth: oncology, pain, inflammation, diabetes, Alzheimers disease and schizophrenia. The acquisition of Wyeth strengthens Pfizers position in a number of these key disease areas, notably Alzheimers disease and inflammation. The long term prospects of the oncology portfolio are also strengthened.

pneumococcal vaccine Prevnar in 2000. Wyeth has focused heavily on Prevnar and Prevnar-13, to the detriment of its development pipeline, resulting in only its Phase II meningitis B vaccine (MnBrLP2086) showing significant market potential. Both Pfizer and Wyeth have a strong presence in hospital antibiotics with revenues of $2.5billion in the seven major markets in 2007 from Zyvox (Pfizers linezolid), Tygacil (Wyeth tigecycline) and Zosyn. Pfizer will now become one of the leading vaccine manufacturers through accessing Wyeths vaccines portfolio

Q.5. There would be a shortage of food Worldwide, what sort of strategy Pfizer should adopt?
Biopharmaceutical research companies are helping people lead longer, more productive and healthy lives. Pfizer should go for diversification strategy and must introduce food brands in emerging food market. Genetically modified seeds can be produced and greater yield will possible if Pfizer will invest in R&D on this side. Ultimately this will generate huge returns for Pfizer along with a best option to remain in market.